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Vitamin D levels and unprotected sun expo-sure as a means of increasing these levels in the general population have become 
hot-button issues, polarizing many in the medical 
community and lay public. Here, we review some 
of the relevant research findings, discuss prevalent 
recommendations based on these data, and offer 
our own recommendations for patient manage-
ment that reflect our evaluation of the literature.
Vitamin D, long known for its essential role in 
calcium absorption and bone health, has more 
recently been implicated in other aspects of 
health, including prevention of cancer, autoim-
mune disease, cardiovascular disease, and other 
chronic diseases (Holick, 2007). A wide range of 
potential functions is suggested by the discovery 
that at least 60 human cell types express the vita-
min D receptor and more than 200 genes have 
been identified as directly or indirectly responsive 
to vitamin D (Holick, 2007). These discoveries 
have led to understandable speculation that sub-
optimal vitamin D levels may predispose individ-
uals to many diseases. It is unfortunate for lifelong 
maintenance of healthy skin that the increased 
interest in vitamin D has also led some to advo-
cate unprotected sun exposure or sun bed use to 
attain “sufficient” or optimal levels (Holick, 2007; 
Schoenmakers et al., 2008). Because of space 
constraints, we have assumed the reader has a 
basic knowledge of the rationale for photoprotec-
tion, which includes prevention of photocarcino-
genesis and photoaging. We discuss instead often 
poorly articulated issues that fuel the “vitamin D 
controversy” and appear to lead otherwise well-
informed health-care providers to recommend 
unprotected UV exposure to their patients.
terms and definitions
Vitamin D level commonly refers to the serum 
concentration of the inactive storage form, 
25-hydroxyvitamin D (25(OH)D), understood to 
reflect total body stores. The active form of the 
vitamin, 1,25-dihydroxyvitamin D (1,25(OH)2D), 
is more correctly viewed as a hormone, because 
it can be made by the body and is transported 
in the bloodstream to the target tissues possess-
ing its nuclear receptor, a member of the steroid 
hormone superfamily (Holick, 2007). In contrast 
to 1,25(OH)2D levels, which are tightly regulated 
and virtually constant, serum 25(OH)D levels 
vary widely among apparently healthy individu-
als and over time in a single individual (Dawson-
Hughes et al., 1997; Nesby-O’Dell et al., 2002; 
Tangpricha et al., 2002).
Irradiation of animal skin with UVB (290–315 
nm), the same wavelengths primarily respon-
sible for photocarcinogenesis (Wolpowitz and 
Gilchrest, 2006), converts 7-dehydrocholes-
terol in cell membranes to pre–vitamin D3, 
which then thermally isomerizes to vitamin D3 
(cholecalciferol) and enters the bloodstream. In 
an analogous process in plants and fungi, UV 
irradiation converts ergosterol in cell walls to 
vitamin D2 (ergocalciferol or calciferol), which 
upon oral ingestion also enters the bloodstream. 
Ingestion of certain fish or other animal prod-
ucts, as well as either vitamin D2 or D3 supple-
ments, also results in entry of vitamin D into the 
bloodstream. Both forms of the vitamin, D2 and 
D3, are measured in standard vitamin D serum 
assays after hydro xylation in the liver, and both 
are further hydroxylated to biologically active 
1,25(OH)2D (Holick, 2007).
Classically, there are three categories for 
vitamin D levels. The first level is deficient, a 
level causing bone disease (rickets in children 
or osteomalacia in adults), usually defined as 
<10–20 ng/ml or 25–50 nmol/l (Holick, 2007; 
Schoenmakers et al., 2008). Signs and symptoms 
of vitamin D deficiency are rapidly abolished by 
increasing 25(OH)D levels through supplementa-
tion or UV exposure. The next level is normal, any 
level between deficient and toxic. The third level 
is toxic, a level leading to hypercalcemia, hyper-
calciuria, or associated disorders, usually defined 
as >150 ng/ml or 375 nmol/l. Signs and symptoms 
of vitamin D toxicity, also termed intoxication, are 
rapidly abolished by decreasing vitamin D intake. 
(Because UV exposure in excess of approximately 
one-third a minimal erythema dose promotes con-
version of pre–vitamin D3 to inactive photoprod-
ucts rather than to vitamin D, UV exposure alone 
cannot lead to toxic levels (Holick et al., 1980).) 
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All three categories are strongly influenced by dietary calcium 
ingestion and absorption because the functions of vitamin D 
that determine these signs and symptoms require calcium 
(Wolpowitz and Gilchrest, 2006). The definition of vitamin D 
deficiency sometimes also includes an elevated level of para-
thyroid hormone (PTH), a molecule that stimulates intestinal 
absorption and renal tubular reabsorption of calcium as well as 
renal production of 1,25(OH)2D (Holick, 2007).
More recently, two new terms have been introduced: 
“insufficient” is a level above deficient, as defined here, but 
below a variously defined “sufficient” level. Conceptually, an 
insufficient level is statistically associated in one or more epi-
demiologic studies with a higher incidence or prevalence of a 
disease of interest such as cancer, cardiovascular disease, or 
diabetes. It is hypothesized on the basis of indirect evidence 
that a very high serum 25(OH)D level drives the inactive 
vitamin into cells that express 1-hydroxylase, where it is then 
converted to active 1,25(OH)2D and exerts healthful effects 
such as differentiation, thus decreasing cancer risk, for exam-
ple (Autier and Gandini, 2007; Bischoff-Ferrari et al., 2006; 
Holick, 2008). Typically, to determine a sufficient level, stud-
ied populations have been divided into quartiles or quintiles 
based on 25(OH)D levels and the disease of interest found to 
be increased 1.5- to 2-fold among subjects in the lowest group 
relative to the highest group (Giovannucci, 2005; Melamed 
et al., 2008). The proportion of affected individuals is low in 
all subject groups, typically 0.5–2% (Freedman et al., 2008; 
Wactawski-Wende et al., 2006), and thus the overwhelm-
ing majority of “insufficient” subjects do not have the disease 
of interest. Because each study selects somewhat different 
25(OH)D levels as cutoffs within the population, numerous 
values have been suggested as the lower limit of “sufficient.”
A recent consensus conference of five investigators inter-
ested in this issue recommended 30–40 ng/ml (75–100 nmol/l) 
(Bischoff-Ferrari et al., 2006), but some publications and many 
Internet blogs recommend cutoffs up to twice this level (Hollis 
et al., 2007; GrassrootsHealth, 2008; Looking Fit, 2008). Some 
definitions of “sufficient” include the criterion that PTH levels 
be maximally suppressed—i.e., not lowered further by increas-
ing 25(OH)D levels (Holick, 2007)—but PTH levels are rarely 
measured in clinical practice and even more rarely before 
and after vitamin D challenge. In any case, the desirability of 
keeping PTH levels at their nadir, incapable of reduction by 
further elevation of 25(OH)D levels, is philosophical: no study 
has demonstrated a health benefit of minimizing PTH levels in 
normal individuals. 
Of note, by definition, an individual need not have any past, 
present, or future health problem to be classified as vitamin D 
insufficient. Equally, there need be no detectable benefit of 
increasing an individual’s 25(OH)D level, even for a period of 
years; and individuals classified as sufficient are still at risk for 
all the studied diseases.
the effect of obesity on vitamin d levels
As a fat-soluble molecule, 25(OH)D dissolves in fat, and thus 
serum measurements of vitamin D tend to decrease with 
increasing body mass index (Giovannucci, 2005; Holick, 2007). 
Whether 25(OH)D in fat is as bioavailable as it is when protein 
bound in the serum is debatable, but serum vitamin D levels 
in overweight or obese persons under estimate their total body 
stores (Wortsman et al., 2000) and are considerably lower than 
in leaner individuals in similar environ ments (Arunabh et al., 
2003; Kumar et al., 2009), placing them disproportionately 
in the lower quartiles and quintiles of populations stratified 
by 25(OH)D level. A recent study reporting an association of 
hypertension, diabetes, and other cardiovascular risk factors 
with low 25(OH)D levels in children and adolescents claims 
that the association persists when the data are analyzed after 
correcting for adiposity (Kumar et al., 2009), but in fact their 
subanalysis omits only those above the 95% cutoff in weight 
for infants and those with body mass index >30 kg/m2 for 
older children, leaving many severely overweight participants. 
Thus, obesity remains a likely confounding factor for many, if 
not all, of the associations between low 25(OH)D levels and 
poor health outcomes. Of course, it is possible, if seemingly 
far-fetched, to argue the reverse—that obese and sedentary 
people are at high risk of many diseases specifically because 
they have low serum 25(OH)D levels (Garland et al., 2007; 
Giovannucci, 2005).
Interestingly, in the context of considering how best to cor-
rect vitamin D insufficiency in the population, lean and obese 
subjects are reported to comparably increase serum 25(OH)D 
levels after a standardized oral supplement, but following a 
whole-body UVB exposure obese subjects appear to increase 
25(OH)D levels less than half as much as lean subjects 
(Wortsman et al., 2000).
Prevalent recommendations for vitamin d supplementation
The current official daily recommendation for adequate 
intake of vitamin D is 200–600 international units (IU)/day 
(American Academy of Dermatology, 2009), depending 
on age, although this is under review and may be revised 
upward as early as May 2010 (Grant and Boucher, 2009). 
These amounts were calculated by committee, from assump-
tions about typical sun exposure and dietary intake, and 
are intended to ensure a serum 25(OH)D level in the pre-
sumptively adequate range (US National Institutes of Health, 
2009). Most multivitamins accordingly contain 400 IU of 
vitamin D.
Recommendations for higher levels of supplementation 
have flooded the literature and the Internet. Most appear based 
on intervention studies that demonstrate a statistically signifi-
cant health benefit of 700–1100 IU/day of vitamin D (plus 
1.0–1.5 g/day of calcium) as an oral supplement (Bischoff-
Ferrari et al., 2006; Lappe et al., 2007). To date, such studies 
have involved primarily elderly women, many of whom were 
initially vitamin D deficient (not “insufficient”), and pertain 
largely to reduction in falls and fractures (Wolpowitz and 
Gilchrest, 2006). No study has documented any benefit of sup-
plementation greater than 700–1200 IU/day.
It is estimated that for every 100 IU of vitamin D2 or D3 
ingested daily, serum 25(OH)D levels increase 1.0 ng/ml, or 
2.5 nmol/l (Heaney et al., 2003; Holick, 2008), suggesting that 
in the complete absence of dietary vitamin D or UV exposure, 
a daily supplement of at least 1,000 IU is needed to avoid vita-
min D deficiency, defined as <10 ng/ml, or <25 nmol/l.
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Others base their vitamin D recommendation on the belief 
that the natural state of humans (implied to be optimal) is 
living outdoors in the sun scantily clothed, a condition best 
mimicked in today’s world by lifeguards at the beach, who 
maintain serum 25(OH)D levels of up to 130–190 nmol/l 
(Haddad and Chyu, 1971; Hollis et al., 2007). In the absence 
of sun exposure, this requires a vitamin D supplement of at 
least 5,300 IU/day (Heaney et al., 2003). Still others recom-
mend supplements of up to 10,000 IU/day (Looking Fit, 2008), 
without a specific rationale, although this level of supplemen-
tation for 5 months has been reported not to cause vitamin D 
toxicity (Holick, 2007).
Most authorities recommend oral supplements containing 
vitamin D3 because vitamin D2 has been reported to be sub-
stantially less stable (Holick, 2007; Houghton and Vieth, 
2006). However, vitamin D2 appears to raise 25(OH)D levels 
as effectively as the D3 form (Holick, 2008). Only one author-
ity has suggested that vitamin D3 produced by cutaneous 
sun exposure is more healthful than vitamin D3 supplements 
(Holick, 2009).
Should 25(oH)d levels be monitored?
Serum 25(OH)D levels are increasingly being recommend-
ed as part of routine patient monitoring (Weinstock and 
Moses, 2009). However, the recommended treatment for 
vitamin D insufficiency is supplementation with 1,000 IU/
day (American Academy of Dermatology, 2009; Bischoff-
Ferrari et al., 2006; Holick, 2007), at a cost of less than 
$20/year (as of December 2009, a nationwide pharmacy 
charged $11.49 for 240 1,000-IU tablets) versus $45–$65 
or more per serum determination (Centers for Medicare and 
Medicaid Services, 2009). Hence, 25(OH)D levels seem 
indicated only in cases of unexplained signs and symp-
toms consistent with vitamin D deficiency or toxicity or in 
patients considering high-dose supplementation while preg-
nant (to avoid the teratogenic effects of very high 25(OH)D 
levels) or at known risk of hypercalcemia or hypercalciuria. 
If an apparently healthy individual or his or her physician is 
concerned about the possibility of vitamin D insufficiency, 
oral vitamin D supplementation of 1,000 IU daily appears to 
be the logical choice, because whatever the 25(OH)D level, 
by some standard it will likely be insufficient, and risk of 
toxicity at this dose is negligible. Patients with malabsorp-
tion or other disorder that interferes with vitamin D homeo-
stasis should be under the care of an appropriate specialist 
and monitored as indicated.
What is the evidence that very high vitamin d levels  
are healthful?
Any discussion of this topic is complicated by the huge 
numbers of publications, including more than 5,500 studies 
addressing the relationship of “vitamin D” and “cancer,” for 
example (the result of a search of PubMed on 27 September 
2009). Because no single review can critique the entire body 
of literature, each review tends to selectively discuss stud-
ies that support the authors’ biases—or at least can easily be 
accused of doing so. In addition, many reviews and editorials 
cite not only a favorite study but also multiple other reviews 
and editorials that cite the same study, creating for the casual 
reader an impression of overwhelming evidence in support 
of the conclusion when in fact the data are modest.
There is consensus, however, that the strongest evidence 
for a beneficial effect of high 25(OH)D supplements has 
been generated for reducing falls and bone fractures and, 
less so, a reduction in cancer risk, especially for colorectal 
cancer. Reductions in breast cancer risk and overall mor-
tality are also frequently cited (Autier and Gandini, 2007; 
Garland et al., 2007; Giovannucci, 2005).
Supplements of 700–800 IU/day of vitamin D with or 
without calcium reduced falls and hip and nonvertebral frac-
tures in meta-analysis of randomized, prospective, placebo-
controlled trials in frail elderly women (Bischoff-Ferrari 
et al., 2004, 2005). One randomized controlled trial, using 
1,100 IU/day vitamin D with 1.5 gm/day calcium, evaluated 
a secondary end point, self-reported cancer incidence, and 
demonstrated a statistically significant reduction in supple-
mented subjects if the analysis was restricted to women 
who were cancer-free 1 year after beginning supplementa-
tion and were then followed for 3 years (Lappe et al., 2007). 
However, several methodologic concerns have been raised 
regarding this study (Bolland and Reid, 2008; Ojha et al., 
2007; Schabas, 2008; Sood and Sood, 2007).
Several randomized prospective placebo-controlled trials 
of 400 IU/day vitamin D, usually with 800–1,000 mg/day 
calcium, failed to show a benefit of supplementation in a 
range of diseases selected because at least one epidemio-
logic study had previously revealed an association with low 
25(OH)D levels. The studies include the Women’s Health 
Initiative study of >36,000 women (average age 62 years) 
followed on average for 7 years, which failed to demonstrate 
a reduction in incidence, morbidity, or mortality for col-
orectal cancer (Wactawski-Wende et al., 2006). Subsequent 
analysis of the same population investigating other possible 
benefits of vitamin D and calcium supplementation sug-
gested by prior epidemiologic studies further revealed no 
significant impact on overall mortality, coronary or other 
cardiovascular death, cerebrovascular death, or total can-
cer deaths (LaCroix et al., 2009). There were modest and 
nonsignificant reductions in fractures of the hip and verte-
brae (Jackson et al., 2006). Although the Women’s Health 
Initiative studies have been discounted by many in the field 
for using too small a supplement, they remain the largest 
and best controlled efforts to date to implicate vitamin D in 
health outcomes.
Negative results were also noted in a prospective study of 
nearly 17,000 subjects recruited from the National Health 
and Nutrition Examination Survey study and followed up to 
12 years; there was no effect of 25(OH)D level on mortality 
risk for five of six cancer types or for overall cancer mortality 
(Freedman et al., 2007). Subsequently, these investigators per-
formed numerous additional analyses of the data in response 
to the suggestion that they might have missed important 
associations detected in previous smaller studies by failing 
to account for race or season of the 25(OH)D determination 
or to separately examine only subjects with low 25(OH)D 
levels. All these analyses, and more, yielded no additional 
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associations between cancer mortality and 25(OH)D levels 
(Freedman et al., 2009). Studying a second independent 
large population of postmenopausal women, these inves-
tigators also found no relationship between breast cancer 
risk and baseline levels of either 25(OH)D or 1,25(OH)D, 
also suggested by some to affect multiple health outcomes 
(Freedman et al., 2008).
What’s concerning about the definition  
of vitamin d insufficiency?
More than one-half to three-fourths of many studied popu-
lations of apparently healthy people are now classified as 
vitamin D insufficient (Ginde et al., 2009; Holick, 2007), 
and it is suggested that they are at increased risk of dis-
ease or early death and require interventions whose long-
term risks are unknown. From a dermatologic perspective, 
the major concern is the position of the Indoor Tanning 
Association and a small number of authors who advocate 
increased UV exposure as the best way to correct this situ-
ation, despite the anticipated increases in skin cancer, 
including melanoma, and photo aging. From a broader pub-
lic health perspective, however, other problems exist.
First and most critically, having the media and certain 
physician groups propagate alarmist health messages that 
later prove to be incorrect may cause needless fears and 
ultimately undermine public confidence in all public health 
messages. Although of interest and deserving of further 
study, the epidem iologic associations observed between low 
25(OH)D levels and various diseases—in some studies (Crew 
et al., 2009; Garland et al., 2007; Holick, 2007) but certain-
ly not all (Arslan et al., 2009; Freedman et al., 2008, 2009; 
Giovannucci, 2005; Grant and Boucher, 2009; Wolpowitz 
and Gilchrest, 2006)—do not establish cause and effect. In 
our opinion, this must be done in prospective, randomized, 
double-blind trials in which vitamin D supplementation is 
compared with placebo. To determine musculoskeletal and 
at least some other benefits, calcium intake and supplemen-
tation should also be controlled (Wolpowitz and Gilchrest, 
2006). Prospective randomized controlled trials are required 
to eliminate the possibility that already reported statistical 
associations are not confounded by obesity, sedentary life-
style, or other factors known to incidentally lower 25(OH)D 
levels and to predispose individuals to many of the diseases 
being attributed by some to vitamin D insufficiency. Others 
disagree with the need for such trials, noting that a prepon-
derance of non randomized, noncontrolled studies supports 
a healthful effect of high 25(OH)D levels and that the scien-
tific community is simply resistant to new ideas (Grant and 
Boucher, 2009).
Second, authorities in the endocrine and renal com-
munities warn that potential risks of long-term high-dose 
vitamin D supplementation (>1,000 IU/day) are unknown. 
For example, studies of modest supplements (400 IU/day), 
far below the levels now being widely advocated, increased 
the incidence of kidney stones in well-controlled stud-
ies (Jackson et al., 2006; Wactawski-Wende et al., 2006). 
Although these risks are probably small, any risk must be 
weighed against an established benefit.
Why worry about a recommendation for modest  
unprotected sun exposure to generate vitamin d?
Recommendations by the American Academy of Dermatology 
(2009) and leading dermatologists for daily use of high-SPF (sun 
protection factor) sunscreens by almost everyone have been 
ridiculed by some as excessive or criticized as evidence of bias 
toward the sunscreen industry. However, typical sunscreen use 
has not been shown to induce vitamin D insufficiency (Norval 
and Wulf, 2009). Typical recommendations for “modest” UV 
exposure suggest 5–30 minutes, depending on skin type, lati-
tude, and season, to arms and legs only, three times a week 
(Holick and Jenkins, 2004). Even the Australian College of 
Dermatologists (2005) recommends unprotected sun exposure, 
ranging from less than 5 minutes to 2–3 hours, depending on 
season and region of residence, to face, arms, and hands and 
only when the UV index is low to moderate, although persons 
at high risk for skin cancer are advised to consult a physician.
Concerns with recommending time- and site-limited unpro-
tected sun exposure include the following: (i) few persons suc-
cessfully limit their sun exposure to restricted sites for a brief and 
quite highly variable period determined by difficult-to-judge 
UV intensity, (ii) most daily sunscreen users already achieve 
adequate (Australian College of Dermatologists, 2005) or even 
maximal (Gilchrest, 2008) vitamin D in exposed skin during 
incidental exposures, and (iii) the message is easily distorted 
by the Indoor Tanning Association and others who tell the pub-
lic that doctors support regular unprotected UV exposure year 
round, for example, through sun bed subscriptions (Gilchrest, 
2008; Holick, 2009; LA Tan, 2009; TanningTruth.com, 2009). 
It is apparent that most sunbathers (largely fair-skinned young 
people) seek UV exposure not to improve their health but to 
tan over most or all of their body surface. Any recommendation 
for unprotected UV exposure, however modest, is interpreted 
as an endorsement of their tanning behavior.
Why is modest unprotected sun exposure inferior to  
oral vitamin d supplementation as a public health message?
Whether or not one believes that one-half to three-fourths of 
the entire population of Europe and the United States is suffer-
ing from impaired health due to vitamin D insufficiency, there 
is strong evidence that lack of vitamin D is a health problem for 
some persons with darkly pigmented skin and for many elderly 
persons (Holick, 2007; US National Institutes of Health, 2009; 
Webb, 2006). These groups often limit their sun exposure for 
reasons unrelated to skin cancer concerns and are unlikely 
to use sunscreen daily. They also photosynthesize vitamin D 
inefficiently because of, respectively, a high epidermal content 
of melanin that absorbs UV photons and epidermal atrophy, 
which reduces the amount of available 7-dehydrocholesterol, 
the vitamin D precursor (Holick, 2007; Webb, 2006). In con-
trast, their absorption of oral vitamin D is not impaired relative 
to fair-skinned or younger groups (Harris and Dawson-Hughes, 
2002; Talwar et al., 2007).
If very high vitamin D levels are truly desirable, sun expo-
sure is an unreliable means of achieving them. Effective UV 
wavelengths (290–315 nm) are present in sunlight for only part 
of the year over much of the earth’s surface because of the sun’s 
zenith angle (Webb, 2006). Above 40°N latitude (encompassing 
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Philadelphia, New York, Boston, Portland (both Oregon and 
Maine), and all of Europe above central France), for example, 
detectable photosynthesis of vitamin D does not occur dur-
ing sun exposure for at least 4 months of the year (Webb et al., 
1988). Inadequate exposure occurs even in generally sunny 
parts of the world; for example, in a cohort of 93 healthy, lean 
young men in Hawaii (latitude 21°N), most recruited from a surf 
shop and averaging 29 hours/week of direct, largely unprotect-
ed sun exposure over the preceding 3 months, more than half 
were classified as vitamin D insufficient with 25(OH)D levels 
<30 ng/ml (75 nmol/l) (Binkley et al., 2007). This suggests that 
the reasonable-sounding recommendations for very modest 
sun exposure would not in practice raise 25(OH)D levels suf-
ficiently in the opinion of many. Sun bed use, proposed as an 
alternative to sun exposure during the winter (Holick, 2007), is 
virtually nonexistent in the demographic groups at highest risk 
for vitamin D deficiency and customarily entails exposures that 
far exceed those from casual sun exposure (US Department of 
Health and Human Services, 2005) or that maximize vitamin 
D production (Holick et al., 1980), resulting in needless excess 
photodamage and increased risk of skin cancers. Moreover, sun 
bed use (often $3–15/single session or $20/month for unlimited 
sessions) is far more expensive and less convenient than a daily 
oral supplement of 1,000 IU ($0.05 per capsule at several large 
pharmacies), eliminating the common “cost argument” in favor 
of UV exposure versus supplements as a means of increasing 
vitamin D levels. Finally, the cost of UV-induced skin cancer 
to patients and society is billions of dollars annually (Bickers et 
al., 2006).
our conclusions
Individuals at high risk of skin cancer, including persons 
with skin phototype I or II (generally fair-skinned persons), 
those with a personal history of skin cancer, and those with 
numerous or atypical nevi or moles, should wear protective 
clothing, use a high-SPF sunscreen daily, and avoid midday 
sun when possible. Those wishing to minimize photoaging of 
their skin should do the same. Persons at intermediate risk of 
skin cancer should be urged to protect themselves similarly 
at times of anticipated intense sun exposure, such as during 
sunny vacations or outdoor recreation. Everyone should be 
strongly discouraged from using sun beds. Elderly or dark-
skinned individuals who practice safe sun exposure or who 
are infrequently exposed to the sun for any reason should be 
encouraged to take a daily vitamin D3 supplement of 1,000 
IU, preferably with 1 g/day of calcium. Oral supplementation 
of 1,000 IU per day or more can also be safely recommended 
to virtually any adult concerned about his or her vitamin D 
status, especially during the winter months.
Neither the biologic validity of “vitamin D insufficiency” 
nor the health benefit of maintaining high serum 25(OH)D lev-
els has been established for the general population.
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